Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital- anesthetized Dogs

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 6, 2009, Pages 543-551

  Polakowski, James S ^a   King, Andrew J ^a   Campbell, Thomas J ^a   Nelson, Richard A ^a   Preusser, Lee C ^a   Kempf Grote, Anita J ^a   Marsh, Kennan C ^a   Gintant, Gary A ^a   Cox, Bryan F ^a   Mittelstadt, Scott W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Arterial pressure; Cholesteryl ester transfer protein inhibitor; Dog; Heart rate; Torcetrapib; Vascular resistance

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; PENTOBARBITAL; TORCETRAPIB;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CONSCIOUSNESS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEMODYNAMIC PARAMETERS; HYPERLIPIDEMIA; HYPERTENSION; LUNG ARTERY PRESSURE; LUNG VASOCONSTRICTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; VASCULAR RESISTANCE;

ANESTHESIA; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOVASCULAR SYSTEM; CHOLESTEROL ESTER TRANSFER PROTEINS; DOGS; ELECTROCARDIOGRAPHY; HEART RATE; HEMODYNAMICS; MALE; MYOCARDIAL CONTRACTION; PENTOBARBITAL; QUINOLINES; TELEMETRY; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT;

EID: 74949083543     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181bfb158     Document Type: Article

References (21)

1. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992;70:733-737.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
3. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154: 1465-1473.
4. Barter P, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
5. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
6. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497.
7. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781.
8. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27: 257-260.
9. Doggrell SA. The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Exp Opin Pharmacother. 2008;9: 875-1858
10. Banfor PN, Preusser L, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008;294:H238-H248.
11. Van de Water A, Verheyen J, Xhonneux R, et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Meth. 1989;22:207-217.
12. Blacher J, Stassen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160:1085-1089.
13. Scalia GM, Greenberg NL, McCarthy PM, et al. Noninvasive assessment of the ventricular relaxation time constant (t) in humans by Doppler echocardiography. Circulation. 1997;95:151-155.
14. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
15. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58: 32-45.
16. Baldrick P. Safety evaluation to support First-In-Man investigations. I: Kinetic and safety pharmacology studies. Regulatory Toxicol Pharmacol. 2008;51:230-236.
17. Valentin JP, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods. 2008;58:77-87.
18. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta. 2009;403:9-16.
19. Prakash C, Chen W, Rossulek M, et al. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos. 2008;36:2064-2079.
20. Dalvie D, Chen W, Zhang C, et al. Pharmacokinetics, metabolism and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008;36:2185-2198.
21. Joy T, Hegele RA. The end of the road for CETP-inhibitors after torcetrapib? Curr Opin Cardiol. 2009;24:364-371.